Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TMEM51 antisense RNA 2 (TMEM51-AS2) is classified as a long non-coding RNA (lncRNA) gene, officially designated as TMEM51-AS2, with HGNC symbol 32332. It is annotated as an RNA gene with no established coding potential and belongs to the lncRNA class. There is extremely limited information available in the scientific literature or major gene/protein databases regarding its function, biological roles, or disease relevance. Most current knowledge is restricted to its genomic identity and classification as a non-coding RNA. No evidence has been identified to support a direct therapeutic targeting role, biological function, drug interaction, or established disease association for TMEM51-AS2. Important clarification: Much of the available data and functional characterization, especially regarding cancer biology, RNA methylation, and immune regulation, refers to a related lncRNA, TMEM51-AS1, not to TMEM51-AS2. There is a risk of confusion in the literature and databases owing to the similar names, but the available information for TMEM51-AS2 specifically is extremely sparse. If referring to functional or disease relevance, it is likely you meant TMEM51-AS1, which has documented effects as a tumor suppressor in colorectal cancer and roles in RNA methylation, immune modulation, DNA repair, and response to anticancer drugs. TMEM51-AS2 remains an obscure lncRNA without evidence for therapeutic target classification or detailed annotation in current scientific sources. If functionally characterized antisense lncRNAs for TMEM51 are required, TMEM51-AS1 is the molecule of interest with relevant disease and functional annotations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on TMEM51 antisense RNA 2 (TMEM51-AS2).